- Terms of use
- Privacy Notice
- Accessibility
- Cookie Policy
- ©2024 Freeline
Our Gaucher disease and Parkinson’s disease programs reflect our ambition to provide innovative, one-time treatments that change the lives of people with debilitating chronic diseases.
Disease
Research
IND-Enabling
Phase 1/2
Phase 3
Worldwide rights for Freeline
Gaucher Disease Type 1 FLT201
Phase 1/2
Worldwide rights for Freeline
GBA1-linked Parkinson’s Disease
Research
Worldwide rights for Freeline